Aurobindo warned for lax investigations, repeat GMP violations

The US Food and Drug Administration (FDA) hit Indian drugmaker Aurobindo with a warning letter for inadequately investigating batch failures related to its manufacturing of active pharmaceutical ingredients (APIs) and for failing to evaluate the potential effect of changes on its intermediates and APIs.